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Abstract
Background: Homeobox genes are master regulators of cell fate during embryonic development and their expression
is altered in cancer. By regulating the balance between cell proliferation and differentiation, they maintain homeostasis
of normal tissues. Here, we screened the expression of homeobox genes in mammary stem cells to establish their role
in stem cells transformation in breast cancer.
Methods: Using a Homeobox Genes PCR array, we screened 83 homeobox genes in normal cancer breast stem/
progenitor cells isolated by flow cytometry. The candidate gene HOXC8 epigenetic regulation was studied by DNA
methylation and miRNA expression analyses. Self-renewal and differentiation of HOXC8-overexpressing or knockdown
cells were assessed by flow cytometry and mammosphere, 3D matrigel and soft agar assays. Clinical relevance of in
vitro findings were validated by bioinformatics analysis of patient datasets from TCGA and METABRIC studies.
Results: In this study we demonstrate altered expression of homeobox genes in breast cancer stem/progenitor cells.
HOXC8 was consistently downregulated in stem/progenitor cells of all breast molecular subtypes, thus representing an
interesting tumour suppressor candidate. We show that downregulated expression of HOXC8 is associated with DNA
methylation at the gene promoter and expression of miR196 family members. Functional studies demonstrated that
HOXC8 gain of function induces a decrease in the CD44+/CD24-/low cancer stem cell population and proportion of
chemoresistant cells, with a concomitant increase in CD24+ differentiated cells. Increased HOXC8 levels also decrease
the ability of cancer cells to form mammospheres and to grow in anchorage-independent conditions. Furthermore,
loss of HOXC8 in non-tumorigenic mammary epithelial cells expands the cancer stem/progenitor cells pool, increases
stem cell self-renewal, prevents differentiation induced by retinoic acid and induces a transformed phenotype.
Conclusions: Taken together, our study points to an important role of homeobox genes in breast cancer stem/
progenitor cell function and establishes HOXC8 as a suppressor of stemness and transformation in the mammary gland
lineage.
Keywords: Breast cancer, Cancer stem cells, Self-renewal, Differentiation, Homeobox genes, HOXC8
* Correspondence: cinzia.allegrucci@nottingham.ac.uk
1SVMS, University of Nottingham, Sutton Bonington Campus, Loughborough
LE12 5RD, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shah et al. Molecular Cancer  (2017) 16:38 
DOI 10.1186/s12943-017-0605-z
Background
Cancer stem/progenitor cell cells (CSC) are considered
to play an important role in breast cancer complexity as
they retain the fundamental features of normal stem
cells, being able to self-renew and differentiate into the
different cell types that comprise the heterogeneous
tumour mass [1, 2]. Breast CSC have a degree of cellular
plasticity and it is unclear whether they originate from
transformation of normal mammary stem cells (MaSC) or
by reprogramming of differentiated cells to a malignant
phenotype [1].
Genes that are required for tissue development and
normal stem cell plasticity may contribute to the
molecular blueprint of breast CSC and tumorigenesis.
Indeed, it is well established that many molecular path-
ways involved in normal development are altered dur-
ing cancer progression [1]. Amongst the developmental
pathways, homeobox genes function as “master” gene
regulators. They are characterised by a homeodomain
that binds specific DNA elements and encode tran-
scription factors involved in the regulation of cell
growth and differentiation, thus establishing and main-
taining cell identity and fate during development [3].
Given their role, it has been postulated that a balanced
expression of these genes is critical for stem cell func-
tion, especially for self-renewal, differentiation and
quiescence [4]. Within homeobox genes, the HOX gene
family is important in early tissue differentiation. For
instance, the HOXA gene cluster is silenced in pluripo-
tent human embryonic stem cells and epigenetically
reprogrammed and expressed when cells are induced to
differentiate [5]. They also regulate neural and
hematopoietic stem cells function [6, 7].
Homeobox genes are expressed during mammary gland
development and they appear to be regulated both by hor-
mones and extracellular matrix remodelling [8]. Examples
include Hoxc6 and Msx2 being down-regulated and up-
regulated by estrogen and progesterone, respectively.
Msx2 is also regulated by the interaction between epithe-
lial and stromal cells in the gland [8]. Several homeobox
genes are involved in proliferation and differentiation of
mammary stem/progenitor cells. For instance Prrx1, Six1,
Lbx1, Sox9, Msx, Zeb1, Dlx4 have been shown to regulate
epithelial-to-mesenchymal transition (EMT) in mammary
cells, thus promoting stem cell-like characteristics [9–15].
Aberrant expression of homeobox genes has been
reported in several malignancies [4]. Mis-expression of
homeobox genes can lead to abnormal differentiation
and proliferation, leading to a change in cell identity or
homeotic transformation, therefore playing an important
role in carcinogenesis [16]. In cancer, homeobox genes
function as “tumour modulators” as their deregulation
normally involve either up-regulation of genes expressed
in undifferentiated cells or down-regulation of genes
expressed in differentiated tissue, thus acting either as
oncogenes or tumour suppressor genes [17]. Abnormal
expression of homeobox genes leading to loss of differ-
entiation is observed in breast cancer where expression
of Hoxb6, Hoxb7, Hoxc6, Hoxc8, Hoxd4, Hoxd8, Hoxd9,
Hoxd10, Hoxa5 is lost in mouse mammary tumours and
Hoxa1, Hoxd3, Hoxd12, Msx1, Six1 and Oct3 are instead
expressed in cancer, but absent or lowly expressed in the
normal differentiated gland [8]. This deregulated gene
expression has been shown to be involved in neoplastic
transformation by regulating cell cycle, apoptosis, angio-
genesis, metastasis and cell adhesion [8]. Epigenetic
mechanisms, such as DNA methylation, histone modifi-
cation and silencing by non-coding RNA are involved in
the regulation of homeobox gene expression [4]. More-
over, epigenetic silencing of these genes is an early event
in breast carcinogenesis [18–20] and DNA methylation
of homeobox genes is associated with specific breast
cancer cell types and cancer molecular subtypes [21–23].
In this study, we screened the expression of homeobox
genes in breast CSC and demonstrate that a large num-
ber of genes are differentially expressed in immortalised
CSC compared to normal MaSC, in agreement with evi-
dence suggesting an involvement of developmentally-
regulated genes in early stages of cancer transformation.
We also reported expression of homebox genes uniquely
altered in different breast cancer subtypes, which could
represent novel CSC biomarkers for patient stratifica-
tion. Of the genes commonly altered across different
breast cancer molecular subtypes, HOXC8 was chosen
as a putative novel tumour suppressor gene. We show
that HOXC8 downregulation in breast CSC is associated
with epigenetic silencing. Downregulation of HOXC8 in
breast cancer was also found by meta-analysis of breast
cancer data from large cohort studies. Gain of function
of HOXC8 reduced CSC self-renewal and the ability of
cancer cells to grow in anchorage-independent condi-
tions. Conversely, loss of function of HOXC8 in mam-
mary normal cells induced CSC proliferation and colony
formation. In addition, reduced HOXC8 expression
impaired cell differentiation and response to retinoic
acid. Taken together, our study shows that homeobox
genes represent novel biomarkers of breast CSC and that
HOXC8 functions as a novel tumour suppressor gene by
regulating breast CSC proliferation and differentiation.
Methods
Cells and materials
Human mammary epithelial cells (HMEC) were obtained
from Invitrogen and cultured with the proprietary
HuMEC Ready Medium. The immortalised human mam-
mary epithelial cell line MCF10A (ATCC) was cultured in
HuMEC Ready Medium supplemented with 100 ng/ml
cholera toxin. Breast cancer cell lines MCF-7, HCC1954,
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HCC1428 (all from ATCC), MDA-MB-468, MDA-MB-
231, BT549 and Hs578T (all from the NCI-60 cell collec-
tion, CRN cell bank, University of Nottingham) were
grown in RPMI medium supplemented with 10% foetal
calf serum (FCS), 1% Penicillin/Streptomycin (Pen/Strep),
1% L-Glutamine, 1% sodium pyruvate, 1% non-essential
amino acids (NEAA). HEK 293 T (ATCC) cells were
grown in DMEM medium containing 10% FCS supple-
mented, 1% Pen/Strep, 1% L-Glutamine, 1% sodium pyru-
vate, 1% NEAA. Cell lines obtained from ATCC were used
within few passages from the original stocks, whereas other
cell lines were authenticated by STR profiling (Eurofins
Genomics, Germany) using the Promega PowerPlex 21
PCR kit and matched against the ATCC STR database. All
cell lines were tested form mycoplasma contamination
using the EZ-PCR Mycoplasma Test Kit (Geneflow). All
cell culture materials were from Invitrogen and chemicals
from Sigma-Aldrich, unless otherwise stated.
Cell treatments
For chemoresistance assay, cells were incubated with
Paclitaxel (10nM), doxorubicin (500 nM) and 5-
Fluorouracil (5-FU) (500 μM) for 5 days. Viable cells
were trypsinised, collected and the CD44+/CD24-/low
profile was analysed by flow cytometry.
For differentiation experiments, cells were treated with
1 μM all-trans-retinoic acid (ATRA) for 7 days.
Flow cytometry
Stem/progenitor cell populations were identified and iso-
lated as CD44+/CD24-/low by FACS (Beckman Coulter
MoFlo XDP sorter). The following antibodies and isotype
controls were used: FITC-anti-CD44 (eBioscience 11-0441,
1:100 dilution), PE-anti-CD24 (eBioscience 12-0247, 1:20
dilution), APC-anti-CD44 (eBioscience 17-0441, 1:167 dilu-
tion), FITC-anti-CD24 (eBioscience 11-0247, 1:20 dilution),
FITC-rat isotype control (eBioscience 11-4031, 1:100 dilu-
tion), PE-mouse isotype control (eBioscience 9012-4714,
1:20 dilution), APC-rat isotype control (eBioscience 17-
4031, 1:167 dilution), FITC-mouse isotype control
(eBioscience 11-4714, 1:20 dilution). Briefly, 5x105 cells
were incubated with antibodies in the dark at 4 °C for 1 h.
Cells were washed and re-suspended in complete medium
for analysis. For cell sorting, 106 cells in 100 μL of complete
medium were stained as described above. Cells were then
treated with DNase I (Qiagen) in RDD buffer (10 mM Tris-
HCL, 2.5 mM MgCl2, 0.5 mM CaCl2, pH7.6) for at least
15 min at room temperature, and passed through a
40 μm mesh (Becton Dickinson LTD) to avoid cell clump-
ing. Data were analysed with the Weasel software.
Homeobox gene expression array
Total RNA was extracted with the RNeasy Mini Kit
(Qiagen) and cDNA transcribed with the RT2 First
Strand Kit (Qiagen). Expression of homeobox genes was
analysed by real-time PCR (qRT-PCR) using the Homeo-
box (HOX) Genes RT2 Profiler PCR Array (Qiagen) on a
Roche LightCycler® 480 System. Real-time PCR data ana-
lysis was performed by using the RT2 Profiler™ PCR
Array Data Analysis (Qiagen) and based on the ΔΔCT
method with normalization of the raw data to the house-
keeping gene RPLP0 after analysis with the BestKeeper
software [24].
Real-time PCR
Gene expression was analysed by qRT-PCR using
TaqMan® chemistry (Applied Biosystems). Data were
analysed by the ΔΔCT method with normalization to
the housekeeping genes RPLP0. HOXC8 copy number
was measured by qRT-PCR using genomic DNA (ex-
tracted with DNeasy Blood &Tissue kit, Qiagen) and
LuminoCt® SYBR® Green qPCR ReadyMix. miRNAs
were purified from cell pellets using the miRNeasy
Mini Kit (Qiagen) and reverse transcribed with miScript II
RT kit (Qiagen). qRT-PCR was performed using the Lumi-
noCt® SYBR® Green qPCR ReadyMix. Data were analysed
by the ΔΔCT method with normalization to the en-
dogenous control RNU6B. For primers and assay used
see Additional file 1: Table S1.
Bisulfite sequencing
Genomic DNA was isolated using DNeasy Tissue kit
(Qiagen). Bisulfite conversion (200 ng genomic DNA)
was achieved using the EZ DNA methylation kit (Zymo
Research) and 3 μl of bisulfite converted DNA was used
for PCR reaction using the HotStarTaq masterm mix kit
(Qiagen). Primers spanning the CpG island sequence were
designed using the Methprimer software (http://www.uro-
gene.org/cgi-bin/methprimer/methprimer.cgi) (Additional
file 1: Table S1). Bisulfire converted and purified PCR
products were directly sequenced.
Lentiviral plasmids for HOXC8 overexpression and
knockdown
The HOXC8 plasmid was prepared by amplifying
HOXC8 cDNA from HMEC cells using Phusion® high-
fidelity DNA polymerase PCR master mix (New England
Biolabs) and cloning between EcoRI and SpeI sites of a
modified pSIN-EF2-Puro plasmid (pSin-EF2-Nanog-Pur
was a gift from James Thomson, Addgene plasmid #
16578). HOXC8 and scrambled shRNA primers were
constructed using previously reported sequences [25].
shRNA harpins were ligated into AgeI/EcoRI-digested
pLKO-Tet-On plasmid (Tet-pLKO-puro was a gift from
Dmitri Wiederschain, Addgene plasmid # 21915). Plas-
mids were transformed in Stabl3 cells (Invitrogen) and
purified using Qiagen plasmid purification kits (Qiagen).
Viral particles were produced by transfecting HEK
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293 T cells with shRNA or pSIN plasmids, together with
psPAX2 and pMD2.G plamids (gift from Didier Trono,
Addgene plasmids # 12260 and 12259) using FuGENE®6
(Promega). Virus-containing supernatant was collected
at 72 h post-transfection, filtered through 0.45 μm filter
and added of 6 μg/mL hexadimethrine bromide (poly-
brene) (Sigma-Aldrich). Stable transgenic cells were
selected after 72 h using Puromycin (0.75–1 μg/ml).
Tet-inducible shRNA was induced by treatment with
2ug/ml doxycycline.
Western blotting
Nuclear proteins were extracted with NucBuster™ Protein
Extraction Kit (Calbiochem). Extracted proteins were
loaded into a 12% or 15% Acrylamide gel (20 μg/lane),
separated by SDS-PAGE electrophoresis and blotted onto
a PVDF membrane. Membranes were blocked with 5%
skimmed milk and then probed overnight at 4 °C with a
rabbit anti-HOXC8 antibody (1:1,000, Sigma H1791) in
the presence of 0.1% Tween 20 and 5% milk. Membranes
were stripped and the incubated with a mouse anti-Lamin
A/C antibody (1: 2,000, Cell Signalling 4777) overnight
at 4 °C. Peroxidase conjugated donkey anti-rabbit and
sheep anti-mouse (1:10,000; GE Healthcare NA934 and
NA931, respectively) antibodies were incubated for 1 h at
RT. ECL prime kit (GE Healthcare) was used to detect
chemiluminescence.
Mammospheres culture
Single cells were plated in ultra-low adherent flasks
coated with Poly 2-hydroxyethyl methacrylate (Poly-
HEMA) (Sigma-Aldrich) at a density of 2x104 cells/mL.
Cells were grown in mammosphere medium consisting
of Dulbecco’s Modified Eagle Medium: Nutrient Mixture
F-12 (DMEM/F12) supplemented with 20 ng/mL epider-
mal growth factor (EGF, R&D Systems) 20 ng/mL basic
fibroblast growth factor (bFGF) (R&D Systems), 5 μg/
mL insulin, and 1% pen/strep, B27, 4 μg/mL heparin,
and 5 μg/mL hydrocortisone. Cells were incubated at
37 °C and 5% CO2 for 7 days to attain first generation
mammospheres. Formed mammospheres were collected
by gentle centrifugation at 200 × g for 4 min, dissociated
enzymatically with trypsin and mechanically by pipet-
ting. Serial passaging to attain consequent generations of
mammospheres (up to four) was done by re-plating
dissociated mammosphere-derived cells at a density of
5x103 cells/ml and culture for 7–10 days in mammo-
sphere medium. For PKH26 labelled mammospheres,
2x106 cells were stained with 1 μM PKH26 for 5 min,
washed and then and plated in mammosphere medium
for the first generation. After 7 days, mammospheres
were collected, dissociated as described above and sorted
to isolate the PKH26 positivehigh population. Sorted cells
were cultured again in mammosphere medium to obtain
the second generation.
Soft agar assay
Cancer cells (1-3x104 cells/6 well) were seeded in 1 ml of
0.5% noble agar in complete RPMI medium overlaying
2 ml 1% agar in the same medium. MCF10A cells were
instead seeded in HuMEC medium, as described above.
After 2 weeks culture, cell colonies were stained with
0.05% crystal violet in 10% ethanol/PBS for 1 h and col-
onies ≥ of 100 μm counted under a MZ125 Leica
stereomicroscope.
3D Matrigel assay
The 3D on-top Matrigel assay was performed according
to Lee et al. [26]. Cells (1.5x104) were plated into a 4
well plate covered with 120 μl of growth factor reduced
Matrigel (BD Biosciences) and cells allowed to attached
for 30 min. Cells were then cultured in 500 μl HuMEC
Ready Medium supplemented with 100 ng/ml cholera
toxin and 10% Matrigel for up to 7 days, with medium
changed every other day.
Bioinformatics and statistics
For the analysis of the Homeobox gene array, hierarchical
cluster analysis was performed by using the software
ArrayMining (http://www.arraymining.net/). Venn dia-
grams were generated with the online tool Venny (http://
bioinfogp.cnb.csic.es/tools/venny/index.html).
The analysis of copy number variation in clinical datasets
was performed with the software OASIS (OASIS: A Web-
based Platform for Exploratory Analysis of Cancer Genome
and Transcriptome data, www.oasis-genomics.org). Expres-
sion analysis of homeobox genes in TCGA (RNASeq and
PAM50) and METABRIC patient datasets was performed
using the UCSC Cancer Browser (https://genome-cancer.-
ucsc.edu/) and the OASIS portal, respectively [27, 28]. For
the analysis of HOXC8 in the TCGA dataset, clinical
parameters and next-generation RNA sequencing data
(RNAseqv2) were obtained from TCGA ccRCC and normal
non-tumour breast tissue sample set [29, 30]. Patients were
sub-divided depending on clinic-pathological parameters
provided by TCGA. Normalized gene counts (gene counts
rescaled according to library size) from each patient were
compiled into a tab-delimited file for downstream analysis
by RobinA implementation of the Bioconductor-edgeR
software [31, 32]. Expression analysis of HOXC8 in the
METABRIC dataset [33, 34] was also obtained from the
OASIS portal. Methylation analysis of the TCGA dataset
was performed by using the UCSC Cancer Browser and the
MethHC browser (http://methhc.mbc.nctu.edu.tw/php/
index.php) [35].
All data are expressed as mean ± standard deviation.
Comparisons between two samples were done using
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Student’s t-test. One-way or Two-way analysis of variance
(ANOVA) analyses followed by Bonferroni’s multiple
comparison tests were used for multiple group compari-
sons. Statistical analyses were performed with GraphPad
Prism with significance levels set at *P < 0.05, **P < 0.01,
***P < 0.001.
Results
Expression of homeobox genes in breast CSC
In this study we investigated the expression of 83 different
homeobox genes involved in morphogenesis, body pattern
formation, embryonic development, and cellular differen-
tiation in normal MaSC and breast CSC. We used cell
lines representing normal mammary epithelium, immorta-
lised mammary epithelium (IMM) and the breast cancer
molecular subtypes luminal (LUM: ER+, PR+, HER2−),
HER2-enriched (HER2-E: ER−, PR−, HER2+) and basal/
triple negative (TN: ER−, PR−, HER2−). CD44+/CD24-/low
stem cell/progenitor cells were isolated from normal and
immortalised mammary cells (HMEC and MCF10A,
respectively), LUM (MCF-7, HCC1428), HER2-E (MDA-
MB-468, HCC1954) and TN (BT549, Hs578T and
MDA-MB-231) cancer cells. Expression of the majority
(77.11%) of the homeobox genes analysed was altered in
CSC compared to MaSC (CD44+/CD24-/low in HMEC)
across different cancer subtypes (≥2-fold change, with
genes considered differentially expressed only if either up-
regulated or down-regulated in at least 2 cell lines of the
same molecular subtype).
Unsupervised hierarchical cluster analysis showed that
HMEC and MCF10A clustered together, showing a simi-
lar expression of homeobox genes in non-tumorigenic
stem cells. Normal stem cells clustered closer to luminal
CSC, whereas HER2-E and TN CSC clustered separately
(Fig. 1a). Surprisingly, MDA-MB-231 cells clustered with
luminal CSC and not TN CSC, suggesting that this cell
line may have fundamental genetic and epigenetic differ-
ences compared to the other TN cell lines analysed.
A large number of genes were differentially expressed
in immortalised stem cells, suggesting altered expression
of homeobox genes is an early event during CSC trans-
formation. The largest number of differentially expressed
genes was observed in TN CSC. Differential expression
of a large number of genes was consistent across cell
lines of the same molecular subtypes, representing 54.8%
of the genes in LUM, 41.8% in HER2-E, and 72.2% in
TN. A minority of genes changed expression in either only
one cell line within molecular subtypes or in different direc-
tions (either down- or upregulated). The majority of genes
in the immortalised stem cells were downregulated,
whereas upregulated genes were predominant in CSC
across the different molecular subtypes (Additional file 2:
Figure S1A). Of the downregulated genes in the immortal
stem cells, the majority were shared by TN CSC, whereas
upregulated genes were shared similarly by all CSC sub-
types. Interestingly, the TN CSC showed the largest num-
ber of uniquely downregulated and upregulated homeobox
genes (Additional file 2: Figure S1B, Figure S1C). When
considering the cancer subtype-specific homeobox genes,
three genes were unique to LUM CSC, 6 to HER2-E CSC,
and 21 to TN CSC. Nine genes were instead common to all
cancer subtypes (considering at least 2 cell lines) (Fig. 1b).
Of these, six genes were either consistently upregulated
(BARX1, DLX4, HOXB8, PITX2, SIX2) or downregulated
(HOXC8).
The expression of those genes that were differentially
expressed either in all or specific cancer subtypes
(Fig. 1b) was further validated by analysis of large co-
hort patient data from the publically available TCGA
and METABRIC datasets [29, 30, 33, 34]. Figure 2 sum-
marises the validation using TCGA RNASeq (all sam-
ples or samples classified according to their PAM50/
subtype specific signature [30]) and METABRIC data,
with genes upregulated in tumours shown as red and
downregulated in tumours (upregulated in normal tis-
sue) as green (see also Additional file 3: Figure S2). The
majority of homeobox genes altered in breast CSC
showed a good overlap of expression with patient tu-
mours (76.3%; 29/38 genes matching at least one data-
set), confirming the clinical relevance of our findings. Of
the genes that were altered in all cancer subtypes, the ex-
pression of five matched all datasets (HOXC8, HOXC11,
HOXD8, PROX1, SIX2), although the overlap was found
when considering the expression in the majority of the
subtypes as HOXC11 and PROX1 were downregulated in
TN CSC. DLX4 matched two datasets (TCGCA and
PAM50) and BARX1 and PITX1 only the METABRIC
dataset. In contrast, no match was found for HOXB8
expression.
For the luminal-specific genes, HOXA1 was found
downregulated in all datasets, EN2 upregulated in the
METABRIC, and HOXB1 expression showed no overlap.
The genes in the HER2-E subtype corresponded well
with patient data, with HOXC10, HOXC12, PITX1, SIX4
matching all datasets and HESX1 and PDHX the METAB-
RIC and TCGA sets, respectively. Finally, In the TN-
specific gene set, DLX5, HHEX, HOXA9 expression corre-
sponded to all datasets, whereas HOXB9, HOXC6, ISL1,
LBX2, VAX1 only to two datasets (TCGA/PAM50 or
TCGA/METABRIC or METABRIC/PAM50). Interestingly,
of the genes that overlapped with only one dataset (CDX2,
DLX1, DLX6, HOXB2, OTP, PROP1), three matched with
their PAM50 subtype (CDX2, DLX6 and HOXB2). How-
ever, the expression of a number of gene did not corres-
pond to any dataset (DLX2, HOXC9, HOXD3, MEIS1,
MEOX1, NKX3-1, PITX3), suggesting that the expression
of these genes might possibly be specific to the particular
cell lines analysed in this study.
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HOXC8 is downregulated in breast CSC and tumour tissues
Our array data showed HOXC8 downregulation in CSC
compared to normal MaSC, suggesting a possible role as
tumour suppressor gene that regulates normal function
of mammary stem cells. Microarray data was validated
by qRT-PCR, with HER2-E and TN CSC showing most
significant downregulation (Fig. 3a). This expression
profile was mirrored by the unsorted cell lines for
HER2-E and TN subtypes, but not for LUM subtype
(Fig. 3b). In order to extend our analysis of HOXC8 to
clinical samples, we next analysed the expression of
HOXC8 in the latest TCGA [29, 30] and METABRIC
[33, 34] datasets. Analysis of RNA-Seq data of the TCGA
patient tumour samples (n = 1218) revealed HOXC8
expression is lower in primary breast tumours compared
to non-tumour tissue, whereas no difference was ob-
served in metastatic tumours (Fig. 3c). Significant low
expression was also found in TN (ER−/PR−/HER2−)
compared with ER+ tumours (ER+/PR+/HER2+ or ER
+/PR+/HER2−), which is consistent with our findings in
CSC (Fig. 3d). The same profile of expression between
normal and tumour tissue was also shown by the ana-
lysis of the METABRIC dataset (n = 1321) (Fig. 3e, f ).
HOXC8 downregulation in breast CSC is associated with
epigenetic silencing
In order to study the regulation of HOXC8 expression in
breast CSC, we next analysed whether downregulation
could be due to copy number variation or epigenetic
regulation. Analysis of the TCGA [29, 30] and METAB-
RIC [33, 34] breast cancer datasets showed HOXC8 is
rarely deleted in breast cancer and its expression does
not correlate with copy number in breast cancer patients
(Additional file 4: Figure S3). Similarly, cell lines ana-
lysed in this study showed no HOXC8 deletion when
compared to normal mammary epithelial cells (HMEC)
or MCF10A cells (Fig. 4a).
Therefore we focused our attention on the epigen-
etic regulation of HOXC8. Expression of miR196 has
been previously linked to regulation of HOXC8 [36]
and therefore we measured the expression of two
miR196 family members in HER2-E and TN CSC, as
these showed the most downregulated expression of
HOXC8. The expression of miR196-a and miR196-b
was significantly increased in CSC isolated from
MDA-MB-231, but not in CSC isolated from other
cell lines (Fig. 4b). Direct bisulphite sequencing
analysis of the CpG island in the HOXC8 promoter
upstream of the transcription start site revealed high
levels of DNA methylation in all CSC compared to normal
MaSC (Fig. 4c and Additional file 5: Figure S4). A signifi-
cant increase in DNA methylation at the promoter
region of HOXC8 was also observed in the breast
TCGA tumour samples compared to normal tissue
(Fig. 4d), thus demonstrating an important role of
epigenetic modifications in the regulation of HOXC8
expression and the clinical relevance of the in vitro
findings.
Gain of function of HOXC8 reduces CSC self-renewal and
chemoresistance
We next assessed the functional role of HOXC8 in breast
CSC by inducing its expression in cancer cell lines. Con-
stitutive overexpression of HOXC8 in low-expressing cell
lines (BT549, MDA-MB-231, MDA-MB-468) resulted in
high levels of expression both at the RNA and protein
level (Additional file 6: Figure S5). Induced HOXC8 ex-
pression caused a significant reduction in the CD44
+/CD24-/low population (Fig. 5a). The reduction was due
to an induction of differentiation reflected by an in-
creased double positive epithelial cell fraction (CD44
+/CD24+) in both BT549 and MDA-MB-468 cells, but
not in MDA-MB-231. This effect on CSC fate was fur-
ther validated by the increased expression of CD24 and
reduced expression of the CSC marker ALDH1 (Fig. 5b).
To explore whether the increased differentiation induced
by HOXC8 would affect the resistance of cells to chemo-
therapy, we treated control BT549 and MDA-MB-468
cells with the standard of care anti-cancer drugs Pacli-
taxel, Doxorubicin and 5- FU and evaluated the effect of
these drugs on the CSC population. Paclitaxel and 5-FU
increased the number of CD44+/CD24-/low cells after
5 days of treatment, whereas no effect was seen with
doxorubicin (Fig. 5c). Consistent with the significant
decrease in CSC and increased differentiation in these
cell lines, overexpression of HOXC8 caused a significant
reduction in chemoresistant cells (Fig. 5d).
(See figure on previous page.)
Fig. 1 Differential expression of homeobox genes in CSC compared to normal MaSC. a Unsupervised hierarchical clustering of 83 homeobox
genes based on expression in CSC isolated by CD44+/CD24low/- cell sorting of different cell lines representing breast cancer molecular subtypes (LUM,
HER2-E, TN), immortalised mammary epithelial cells (IMM) and normal mammary cells. Homeobox gene expression was determined by qRT-PCR using
using the Homeobox Genes RT2 Profiler PCR Array (Qiagen) with two independent biological replicates. b Venn diagram representing differentially
expressed genes unique or in common among CSC of different breast cancer molecular subtypes compared to normal MaSC (CD44+/CD24-/low cells
from HMEC). Subtype-specific and common differentially expressed genes are indicated in the highlighted boxes




Fig. 2 (See legend on next page.)
Shah et al. Molecular Cancer  (2017) 16:38 Page 8 of 19
To further evaluate the effect of HOXC8 in the regulation
of CSC self-renewal, we performed serial passaging of
mammospheres at clonal density. The reduced CSC
population induced by HOXC8 expression resulted in
a significant reduction in mammosphere formation
over 4 generations for all the cell lines tested (Fig. 6a),
confirming a role of HOXC8 in determining stem cell
fate. As the CD44+/CD24− population can identify both
CSC and early progenitor cells, we also stained HOXC8-
expressing cancer cells with the PKH26 dye and studied the
ability of HOXC8 to regulated the more primitive and qui-
escent CSC population which is able to retain the dye upon
cell proliferation. Therefore after labelling, the first gener-
ation mammospheres were sorted for PKH26positive/high
CSC and new mammospheres formed. Overexpression of
HOXC8 reduced the ability of quiescent PKH26positive/high
CSC to form second generation mammospheres (Fig. 6b).
Finally, HOXC8- overexpressing cells displayed a reduced
growth in soft agar (Fig. 6c), demonstrating a diminished
transformed phenotype.
Loss of function of HOXC8 increases stem cell self-renewal
and transformation
Because of the proposed role of HOXC8 in the regulation
of breast stem cell fate, we next evaluated whether
HOXC8 loss of function in non-tumorigenic mammary
epithelial cells would be responsible for the acquisition of
stemness by differentiated cells. We therefore knocked
down HOXC8 in the immortal but not-tumorigenic
MCF10A cells, as stem cells in this cell line expressed
similar levels of HOXC8 to those isolated from normal
HMEC cells (Fig. 3a). HOXC8 shRNA resulted in about
80% knockdown in gene expression and no detectable
levels of HOXC8 protein (Fig. 7a). HOXC8 knockdown
induced a significant increase in CD44+/CD24-/low cells
with a concomitant decrease in CD44+/CD24+ and CD44
−/CD24+ cells, confirming its role in maintaining a differ-
entiated state in the mammary epithelial lineage (Fig. 7b).
HOXC8 downregulation also increased the number of
mammospheres over several generations (Fig. 7c), indicat-
ing that silencing of HOXC8 is associated with a switch of
cell fate and acquisition of stem cell characteristics.
Reduced HOXC8 expression also resulted in a loss of cell
organisation as cells grown in 3D matrigel appeared to
lose their dome-shaped morphology and acquire a mesen-
chymal/basal phenotype (Fig. 7d). Importantly, HOXC8
knockdown induced a ~ 2.5-fold increase in the number
and size of colonies of MCF10A cells grown in anchorage-
independent conditions compared to the scrambled
control (Fig. 7e, f ), indicating an augmented transformed
phenotype.
Expression of HOXC8 is required for breast stem cell
differentiation
Retinoic acid signalling and HOX genes are important reg-
ulators of embryo development and tissue differentiation
[5, 37] Because our findings revealed a role of HOXC8 in
the regulation of breast CSC self-renewal and differenti-
ation, we next evaluated whether HOXC8 could be in-
volved in the differentiation of mammary cells induced by
retinoic acid. For this experiment, the MCF10A-Tet-
HOXC8 shRNA cell line was treated with retinoic acid for
7 days in presence or absence of doxycyclin to induce
HOXC8 knockdown. As previously indicated [38, 39],
HOXC8 expression can be regulated by retinoids and there-
fore treatment of mammary cells with retinoic acid induced
HOXC8 expression with concomitant increase in the pro-
portion of CD24+ cells after 4 days treatment or CD44
−/CD24− differentiated cells after 7 days (Fig. 8, Additional
file 7: Figure S6). Importantly, HOXC8 knockdown induced
by doxycycline in these cells reduced cell differentiation in-
duced by retinoic acid and both CD24+ and CD44−/CD24−
cell populations, suggesting a role for HOXC8 in the regu-
lation of stem cell fate during differentiation by retinoic
acid signalling in the mammary gland.
Discussion
The importance of developmental genes in the regulation
of cancer stem cell self-renewal and plasticity is well estab-
lished [1, 40]. This study investigated for the first time the
expression of a panel of developmental regulatorsof the
homeobox family in breast cancer stem/progenitor cells.
We found that homeobox genes are deregulated at an
early stage of stem cell transformation as well in different
(See figure on previous page.)
Fig. 2 Data heatmaps and histograms showing expression of homeobox genes in the TCGA (RNASeq and PAM50) and METABRIC datasets.
Genomic heatmaps compare expression of genes between normal and tumour samples, with yellow and blue colour intensity indicating high and low
expression, respectively. The red and green colours under the genomic heatmaps indicate the statistics track showing the logarithmic plot of P-values
for each gene using Student’ t-test followed by Bonferroni’s correction. Bars above the line indicates that the red subgroup (Tumour sample) is greater
than the green subgroup; a bar below the line indicates that the green subgroup (Normal sample) is greater than the red subgroup. Bars are coloured
in red or green when P < 0.05. The same colour code summarises the same information obtained from analysis of the METABRIC and PAM50 datasets
(Additional file 3: Figure S2) and the homeobox PCR array (Fig. 1) in the tables below the heatmaps. a. Homeobox genes differentially expressed in
CSC of all cancer subtypes. b. Homeobox genes differentially expressed in LUM CSC. c. Homeobox genes differentially expressed in HER2-E CSC. d.
Homeobox genes differentially expressed in TN CSC
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cancer molecular subtypes. We found that the majority of
homeobox genes analysed were differentially expressed in
transformed/non tumorigenic breast stem cells, with the
majority being downregulated compared to normal MaSC.
Epigenetic deregulation of homeobox genes is a frequent
and early event in breast cancer. DNA methylation of the
HOX cluster has been reported to be associated with







Fig. 3 HOXC8 expression is reduced in breast CSC and breast cancer clinical samples. a Expression of HOXC8 in CSC sorted as CD44+/CD24low/- cell
population as determined by TaqMan® qRT-PCR. Results are presented as relative fold expression relative to RPLP0 and HMEC used as calibrator (n= 3–4).
Relative fold expression levels were analysed by One-way ANOVA followed by Bonferroni’s multiple comparisons test. *P< 0.05, **P< 0.01, ***P< 0.001. b
Expression of HOXC8 in unsorted cell lines as determined by TaqMan® qRT-PCR. Results are presented as relative fold expression relative to
RPLP0 and HMEC used as calibrator (n = 3–4). Relative fold expression levels were analysed by One-way ANOVA followed by Bonferroni’s
multiple comparisons test. ***P < 0.001. c Expression of HOXC8 in patient tumour tissue determined by RNA-Seq in the breast TCGA dataset
[29, 30]. Statistical analysis was performed by Bioconductor-edgeR. ***P < 0.001. d Expression of HOXC8 in patient tumour tissue classified
according to hormone receptor status as determined by RNA-Seq in the breast TCGA dataset. Statistical analysis was performed by Bioconductor-edgeR.
**P< 0.01, ER+PR+HER2+ (n= 115), ER+PR+HER2− (n= 408), ER−PR−HER2− (n= 128). e Expression of HOXC8 in patient tumour tissue determined by
microarray analysis of the breast cancer METABRIC dataset access through the OASIS software [33, 34]. Statistical analysis was performed by Unpaired
Student’s t-test. ***P< 0.001. f Volcano plot of the METABRIC dataset showing differentially expressed genes in breast cancer patients compared to normal
tissue as visualised in the OASIS software. The significant downregulated HOXC8 expression is highlighted




Fig. 4 (See legend on next page.)
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modulation of early developmental genes plays a role in
escaping cell senescence [19]. In addition, alterations in
DNA methylation of several homeobox genes is found in
ductal carcinoma in situ (DCIS), and low-grade breast tu-
mours [18] [41], with those found in DCIS being associ-
ated with disease progression [42]. These findings suggest
a model whereby stem cells could be the cell of origin of
breast tumours, as developmental genes that are normally
reversibly silenced by polycomb complexes in these cells
[43] become permanently silenced via DNA methylation
during carcinogenesis [40, 44, 45]. Our data support this
hypothesis as the majority of downregulated homeobox
genes in immortal stem cells were also found not to be
expressed or expressed a low level in TN breast cancer, a
molecular subtype particularly enriched in CSC. A num-
ber of homeobox genes were differentially expressed only
in specific breast molecular subtypes. Particularly import-
ant is the finding that the highest number of unique differ-
entially expressed homeobox genes were found in TN
CSC as this molecular subtype of breast cancer is still
poorly understood and does not respond to current con-
ventional or targeted therapies [46, 47]. DNA methylation
profile of different molecular subtypes identified high
enrichment of homebox genes being hypermethylated
specifically in ER− which were associated with high rate of
tumour recurrence and therefore likely contributing to
poor patient outcome [48]. Expression of homeobox genes
have been also found to be specific of TN breast cancer
subtypes, with the MSL (mesenchymal-stem-like) subtype
being particularly enriched [49]. Therefore these newly
identified CSC homeobox genes could represent novel
biomarkers that could be used for patient stratification in
precision medicine and warrant further investigation.
Among the differentially expressed genes identified in
this study, HOXC8 was found consistently downregulated
in CSC and therefore represented a novel putative tumour
suppressor candidate. HOXC8 was especially downregu-
lated in TN and HER2-E CSC and it was also found to be
downregulated in clinical samples of TCGA and METAB-
RIC datasets, strengthening its significance as a potential
biomarker. In line with previous studies reporting the im-
portance of epigenetic regulation of homeobox genes dur-
ing development and carcinogenesis [17], we also found
that HOXC8 silencing is associated with the expression of
miR196 and DNA methylation at the gene promoter re-
gion in CSC. Regulation of HOXC8 via miRNA 196 has
been reported in breast cancer whereby the ration of
miR196 and HOXC8 correlates with cell migration and
metastasis [36] and methylation of the HOXC8 promoter
can induce gene silencing by inducing polymerase II stal-
ling during transcription [50].
Our results demonstrate that HOXC8 is an important
regulator of stem cell self-renewal and that HOXC8 can
act as modulator of cell differentiation in the breast. Using
a combination of strategies and cell culture models, we
show that silencing of HOXC8 confers mammary cells
with stemness potential and this can be reversed by its re-
expression with induction of differentiation. The enhanced
CSC population induced by downregulation of HOXC8 in
mammary cells is also associated with an increase in
transformed phenotype and this observation supports the
notion that breast cell tumorigenicity is enhanced through
acquisition of an undifferentiated state [51]. HOX proteins
are transcription factors that regulate cell proliferation
and differentiation during embryonic development. In
normal adult tissues, they maintain tissue homeostasis by
defining cell fate and lineage commitment [4, 16, 17]. Sev-
eral cancers demonstrate altered expression of HOX genes
but their role in transformation of stem cells and estab-
lishment of CSC is not well-known. Recently, a role in
CSC regulation has been strongly established for HOXA5
in breast and colorectal cancer, whereby HOXA5 can
maintain homeostasis by suppressing stemness in these
tissues [52, 53].
During development, HOXC8 is expressed in the
neural tube and somatic mesoderm and its expression is
essential for skeletal development [54, 55]. HOXC8 is
also expressed in the normal mammary gland [8, 56, 57]
and it participates in the initiation of mammary morpho-
genesis [58]. Previous studies have reported an increased
(See figure on previous page.)
Fig. 4 HOXC8 expression is downregulated in TN and HER2-E CSC by epigenetic silencing. a HOXC8 genomic copy number in CSC sorted as
CD44+/CD24low/- cell population as determined by SYBR® qRT-PCR. Results are presented as fold difference relative to HMEC used as calibrator (n= 4).
Dotted lines represent the range of normal copy number 1 ± 95% confidence interval. b Expression of miR196-a and miR196-b in CSC sorted as CD44
+/CD24low/- cell population as determined by SYBR® qRT-PCR. Results are presented as relative fold expression relative to RNU6B and HMEC used as
calibrator (n= 3). Relative fold expression levels were analysed by One-way ANOVA followed by Bonferroni’s multiple comparisons test. ***P< 0.001. c DNA
methylation profile of HOXC8 promoter CpG Island. DNA methylation was analysed by direct PCR bisulfite sequencing. Black circles indicated methylated
CG dinucleotides, white circles indicate unmethylated CG dinucleotides, white/black semicircles indicate partially methyalted CG dinucleotides. d DNA
methylation profile of HOXC8 promoter of TCGA clinical samples profiled by Illumina Infinium HumanMethylation 450 BeadChip array (n = 872). Left
panel shows DNA methylation normalised proportions in normal and tumour samples as visualised in UCSC Cancer Browser (blue colour
represents lower methylation, red colour represents higher methylation). Right panel shows DNA methylation levels in tumour samples (red)
compared to normal (green) as visualised by MethHC browser. Statistical analysis was performed by Student’s t-test. **P < 0.01
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Fig. 5 HOXC8 expression negatively regulates CSC and chemoresistance. a Representative FACS profiles of cells transduced with pSIN-HOXC8 or
pSIN empty control vector and quantification of CSC and non-CSC populations stained with CD44-APC and CD244-FITC. Results were analysed by
comparing levels of CD44+/CD24−, CD44+/CD24+, CD44−/CD24+ cells in pSIN-HOXC8 transduced cells compared to control vector for each cell
line (n= 3). Statistical analysis was performed by Two-way ANOVA followed by Bonferroni’s multiple comparisons test. **P< 0.01, ***P< 0.001. b Expression
of CD24 and ALDH1A1 in Control and HOXC8-overexpressing cells. Gene expression was measured by TaqMan® qRT-PCR. Results are presented as relative
fold expression relative to RPLP0 and control (pSIN vector) used as calibrator (n = 3). Relative fold expression levels were analysed by Unpaired
Student’s t-test. **P < 0.01, ***P < 0.001. c Percentage of CD44+/CD24low/- cells in cell lines treated with 10nM Paclitaxel, 500 μM 5-FU and
500nM Doxorubicin for 5 days as measured by FACS analysis. Results were analysed by comparing levels of CD44+/CD24low/- cells in untreated
versus treated cells by One-way ANOVA followed by Bonferroni’s multiple comparisons test for each cell line (n = 3). *P < 0.05. d Percentage of
CD44+/CD24low/- cells in cell lines treated with 10nM Paclitaxel, 500 μM 5-FU and 500nM Doxorubicin for 5 days as measured by FACS analysis.
Results were analysed by comparing levels of CD44+/CD24low/- cells in pSIN-HOXC8 or pSIN empty control vector transduced cells by Unpaired
Student’s t-test for each cell line (n = 3). **P < 0.01
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Fig. 6 HOXC8 expression reduced CSC self-renewal and anchorage independent cell growth. a Mammospheres morphology and number obtained
by self-renewal of cell overexpressing HOXC8 or control vector after 4 generations. Mammospheres numbers were compared by Unpaired
Student’s t-test for each cell line (n = 4). *P < 0.05, ***P < 0.001. Only spheres ≥ 100 μM were counted, images were taken at 10X magnification.
b Second generation mammospheres obtained after labelling with the PKH26 dye and sorting of the PKH26 positive/high population from first
generation mammospheres. Results show the morphology of mammospheres overexpressing HOXC8 or control vector and total mammospheres cell
number. Mammospheres numbers were compared by Unaired Student’s t-test (n = 3). **P < 0.01. Only spheres≥ 100 μM were counted, images were
taken at 10X magnification. c Colonies of cells overexpressing HOXC8 or control vector grown in soft agar for 2 weeks. The number of colonies were
calculated by counting 10 fields of view. Results were analysed by Unpaired Student’s t-test for each cell line (n = 3). **P < 0.01, ***P < 0.001. Images
were taken at 10X magnification




Fig. 7 HOXC8 knockdown increase CSC proliferation and transformed phenotype. a Knockdown of HOXC8 was induced by lentiviral transduction
of MCF10A cells with pLKO-Tet-HOXC8 vector and gene expression measured by TaqMan® qRT-PCR. Results are presented as relative fold expression
relative to RPLP0 and pLKO-Tet-Scrambled vector used as calibrator (n = 3). Results were analysed by Unpaired Student’s t-test (n = 3). ***P < 0.001.
Bottom panel shows western blotting of nuclear lysates from cells transduced with pLKO-Tet-HOXC8 vector or pLKO-Tet-Scrambled vector was
conducted to detect the expression of HOXC8 (34 kDa) and LAMIN A/C (41–50 kDa) as loading control. b Percentage of CD44+/CD24low/-, CD44
+/CD24+, CD44−/CD24+ cells after HOXC8 knockdown as measured by FACS analysis. Results were analysed by comparing cell populations levels in
HOXC8 shRNA transduced cells compared to Scrambled shRNA (n = 3). Statistical analysis was performed by Unpaired Student’s t-test. *P < 0.05, **P <
0.01. Representative FACS profiles of cells double stained with CD44-FITC and CD244-PE to analyse the CSC and non-CSC populations are also shown.
c Mammospheres morphology and number obtained by self-renewal of cell after HOXC8 knockdown compared to scrambled control vector after 3
generations. Mammospheres numbers were compared by Unpaired Student’s t-test (n = 3). **P < 0.01. Only spheres≥ 100 μM were counted, images
were taken at 10X magnification. d Colonies of HOXC8 shRNA and Scrambled shRNA cells grown in 3D matrigel. Top panels represents 10X magnification,
bottom panel represents images at 40X magnification. e Colonies of cells with HOXC8 knockdown compared to scrambled control grown in soft agar for
2 weeks. Top images show the whole well stained with crystal violet, bottom images show a representative field of view at 10X magnification.
f The number of soft agar colonies were calculated by counting 10 fields of view. Results were analysed by Unpaired Student’s t-test for each
cell line (n = 3). ***P < 0.001
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expression of HOXC8 during breast cancer progression
that can induce metastasis through direct regulation of
CDH11 and EMB genes [25, 59]. This different role of
HOXC8 suggests that it is possible that this gene could
act as a “modulator” of carcinogenesis and therefore play
either a role as suppressor or driver of transformation
depending on the physiological and pathological context.
Consistent with this, HOXC8 has been implicated in dif-
ferent cancer types, including prostate, cervical, breast,
oesophageal, and pancreatic cancer [36, 60–63]. In these
cancers HOXC8 has been reported to act either as
tumour suppressor gene or oncogene, suggesting that
the function of HOXC8 may depend on the activation or
repression of different HOXC8 targets whose expression
can be tissue-specific. Several targets of HOXC8 have
been characterised [57, 64] and their functional role in
the context of HOXC8 regulation may provide new in-
sights into the role of HOXC8 in different cancer types.
Although an effective approach for inhibition of the
interaction between HOX proteins and co-factors PBX is
available [65], targeting specific HOX proteins still re-
mains a challenge. Therefore, a better definition of HOX
transcriptional regulators and HOX targets could offer
new strategies for therapeutic intervention.
We have also shown that HOXC8 downregulation in
mammary cells can lead to impaired differentiation in
response to retinoic acid, and that the expression of
HOXC8 can be induced by retinoids in normal breast
cells. This role has also been recently demonstrated for
HOXA5, suggesting a prominent role of HOX genes in
the differentiation of the mammary gland [52]. Retinoic
acid has been shown to regulate breast CSC differenti-
ation, reduce mammospheres formation and CSC fre-
quency in combination with chemotherapy [66, 67].
Therefore our study adds to the evidence that HOX
genes are important regulators of stem cell fate and that
differentiation therapy should be considered as a viable
approach to target breast CSC.
Conclusions
This study reports the screening of a large number of
homeobox genes in breast CSC. We show that the expres-
sion of homeobox genes is altered in early-transformed
breast cells and in different breast cancer molecular
subtypes. Altered expression of homeobox genes was also
supported by data obtained from large cohorts of patient
through bioinformatics analysis. Therefore, this screening
provides novel biomarkers that can be used in precision
medicine and as possible targets for CSC-directed therap-
ies. Of the altered genes, HOXC8 demonstrated to function
as a possible novel tumour suppressor in breast CSC by
regulating stem cell self-renewal, differentiation and trans-
formation. Therefore, this study demonstrates the critical
role of homeobox genes in stem cells and paves the way to
larger functional studies to explore the networks involved
in homeotic gene regulation in breast cancer.
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Additional file 1: Table S1. Primers and assays used in the study.
(DOC 41 kb)
Additional file 2: Figure S1. Number of upregulated and
downregulated homeobox genes in immortalised stem cells and cancer
stem cells. a Proportion of up-and downregulated genes in immortalised
mammary stem cells (IMM) and CSC of different breast cancer molecular
subtypes as determined by Homeobox gene expression array. b Number of
downregulated and upregulated genes which are unique or common to CSC
of breast cancer molecular subtypes. c Venn diagrams representing
downregulated and upregulated genes in stem cells of different breast cancer
molecular subtypes. (PDF 204 kb)
Additional file 3: Figure S2. Data heatmap and histograms showing
expression of homeobox genes in the PAM50 (TCGA WGA) (a,b,c,d) and
METABRIC datasets (e,f,g,h). Yellow and blue colour intensity in the
genomic heatmap indicate high and low expression, respectively. The
red and green colours under the genomic heatmap indicate the statistics
track showing the logarithmic plot of P-values for each gene using
Student’ t-test followed by Bonferroni’s correction. Bars above the line
indicates that the red subgroup (Tumour sample) is greater than the
green subgroup; a bar below the line indicates that the green subgroup
(Normal sample) is greater than the red subgroup. Bars are coloured in
red or green when P < 0.05. (PDF 63 kb)
Additional file 4: Figure S3. HOXC8 copy number variation in the
breast TCGA and METABRIC studies. Bar plots and scatter plots
representing the copy number variation and correlation with gene
expression in patient samples from the TCGA and METABRIC datasets
[29, 30, 33, 34]. (PDF 271 kb)
Additional file 5: Figure S4. Sequencing chromatograms of bisulfite
converted HOXC8 CpG island PCR products. Bisulfite converted DNA
extracted from CSC was amplified by PCR and then directly sequenced.
Chromatograms show the average DNA methylation of the PCR
products. CG residues are circled. A TG peak indicated unmethylated C,
T/G peak indicates partially methylated C, CG peak indicates methylated
C. (PDF 311 kb)
Additional file 6: Figure S5. HOXC8 overexpression in TN and HER2-E
cells. Overexpression of HOXC8 was induced by lentiviral transduction
with pSIN-HOXC8 vector and gene expression measured by TaqMan®
(See figure on previous page.)
Fig. 8 HOXC8 downregulation prevents differentiation of MCF10A cells induced by retinoic acid. a Representative FACS profiles and percentage
of CD44+/CD24low/-, CD44+/CD24+, CD44−/CD24+ cells after retinoic acid (ATRA) treatment for 4 days and HOXC8 knockdown induced by
doxycyclin (n = 3). Statistical analysis was performed by One-way ANOVA followed by Bonferroni’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P
< 0.001. b Representative FACS profiles and percentage of CD44+/CD24low/-, CD44+/CD24+, CD44−/CD24+ cells after retinoic acid (ATRA) treatment for
7 days and HOXC8 knockdown induced by doxycyclin (n = 3). Statistical analysis was performed by One-way ANOVA followed by Bonferroni’s multiple
comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001
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qRT-PCR. Results are presented as relative fold expression relative to
RPLP0 and control (pSIN empty) vector used as calibrator (n = 3). Relative
fold expression levels were analysed by Unpaired Student t-test. ***P <
0.001. Bottom panel represents Western Blotting of nuclear lysates from
cells transduced with pSIN-HOXC8 overexpressing vector or control
vector was conducted to detect the expression of HOXC8 (34 kDa) and
LAMIN A/C (41-50 kDa) as loading control. (PDF 92 kb)
Additional file 7: Figure S6. Expression of HOXC8 and CD24 in ATRA
treated cells. Expression of HOXC8 and CD24 in MCF10A-Tet-HOXC8 shRNA
cells measured by TaqMan® qRT-PCR. Results are presented as relative fold
expression relative to RPLP0 and control (shRNA with no doxycyclin) used as
calibrator (n = 3). Relative fold expression levels were analysed by One-way
ANOVA followed by Bonferroni’s multiple comparisons test. *P < 0.05, **P <
0.01, ***P < 0.001. (PDF 52 kb)
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